Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3305845 | 1.00 | CTSK (0.54) | CTSKCTSSBCHEACHECTSL | |
| SCHEMBL3307597 | 0.98 | CTSK (0.54) | CTSKCTSSBCHEACHECTSL | |
| SCHEMBL3309275 | 0.92 | CTSK (0.54) | CTSKCTSSBCHEACHECTSL | |
| SCHEMBL28438703 | 0.89 | CTSK (0.52) | CTSKCTSSBCHEACHECTSL | |
| SCHEMBL3313127 | 0.88 | CTSK (0.53) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL3303326 | 0.88 | CTSS (0.53) | CTSKCTSSCTSLCTSBACE | |
| SCHEMBL3303330 | 0.88 | CTSS (0.53) | CTSKCTSSCTSLCTSBACE | |
| SCHEMBL3308323 | 0.86 | CTSS (0.54) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL13396474 | 0.85 | CTSK (0.62) | CTSKCTSSCTSLCTSB | |
| SCHEMBL28438702 | 0.84 | PPARA (0.59) | CTSKCTSSCTSLCTSBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635816-B1 | ENALAPRIL-NITROXYDERIVATIVES DERIVATIVES AND RELATED COMPOUNDS AS ACE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX SA (FR) | 2009-03-04 | — | — | EP | disclosed |
| US-7217733-B2 | ACE inhibitor derivatives | NICOX, S.A. (FR) | 2007-05-15 | — | — | US | disclosed |
| EP-1635816-A1 | ENALAPRIL-NITROXYDERIVATIVES DERIVATIVES AND RELATED COMPOUNDS AS ACE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Nicox S.A. (FR) | 2006-03-22 | — | — | EP | disclosed |
| US-20050004100-A1 | ACE inhibitor derivatives | NICOX S.A. (FR) | 2005-01-06 | — | — | US | disclosed |
| WO-2004110432-A1 | ENALAPRIL-NITROXYDERIVATIVES DERIVATIVES AND RELATED COMPOUNDS AS ACE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX S.A. (FR) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004100-A1 | ACE inhibitor derivatives | ACE, ACE2, AGTR1 | CTSK 559/4885CTSS 544/4885BCHE 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.